Ocular Therapeutix Advances AXPAXLI for Wet AMD Despite Rising Costs
Ocular Therapeutix (NASDAQ:OCUL) is on track to submit its new drug application (NDA) for AXPAXLI, a treatment for wet age-related macular degeneration (AMD), in Q4 2026. The FDA has endorsed the company's plan following a Type C meeting and confirmed that data from the SOL-1 trial will support the NDA filing under the accelerated 505(b)(2) pathway. The drug shows potential to reduce injection frequency by up to 72% compared to current therapies, which could improve patient adherence. Market research indicates strong physician interest in AXPAXLI if approved. However, Ocular's financials show rising costs: R&D spending increased year-over-year and the company reported a wider net loss of $78.8 million for Q2 2026. The SOL-R trial’s efficacy results are expected in early 2028, while cash reserves have dropped to $598.6 million as of June 30 from around $737.1 million at the end of 2025.
Tickers: $OCUL
Topics: clinical trials drug development retinal disease treatment